Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antibodies, Bacterial | 10 | 2019 | 510 | 2.48 | Why? |
| Pneumococcal Vaccines | 7 | 2019 | 571 | 1.50 | Why? |
| Streptococcus pneumoniae | 5 | 2019 | 827 | 1.33 | Why? |
| Immunization, Secondary | 11 | 2021 | 1649 | 1.28 | Why? |
| Immunization Schedule | 5 | 2021 | 1305 | 1.23 | Why? |
| Pneumococcal Infections | 4 | 2019 | 562 | 1.12 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2018 | 64 | 0.87 | Why? |
| Tetanus Toxoid | 2 | 2018 | 136 | 0.81 | Why? |
| Typhoid Fever | 2 | 2018 | 139 | 0.79 | Why? |
| Typhoid-Paratyphoid Vaccines | 1 | 2018 | 34 | 0.74 | Why? |
| Polysaccharides, Bacterial | 1 | 2018 | 59 | 0.73 | Why? |
| Meningococcal Vaccines | 2 | 2017 | 225 | 0.70 | Why? |
| Immunity, Maternally-Acquired | 1 | 2017 | 179 | 0.60 | Why? |
| Immunogenicity, Vaccine | 7 | 2021 | 4624 | 0.55 | Why? |
| Vaccines, Conjugate | 4 | 2019 | 328 | 0.49 | Why? |
| Single-Blind Method | 6 | 2021 | 1283 | 0.47 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.46 | Why? |
| Vaccines | 2 | 2021 | 3692 | 0.42 | Why? |
| Paratyphoid Fever | 2 | 2017 | 19 | 0.34 | Why? |
| Serogroup | 3 | 2019 | 510 | 0.33 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.30 | Why? |
| Nepal | 3 | 2019 | 1004 | 0.29 | Why? |
| Antibody Formation | 3 | 2021 | 4038 | 0.25 | Why? |
| Infant | 12 | 2019 | 30274 | 0.23 | Why? |
| Salmonella paratyphi A | 2 | 2017 | 22 | 0.22 | Why? |
| Salmonella typhi | 2 | 2018 | 98 | 0.21 | Why? |
| Immunologic Memory | 3 | 2017 | 3362 | 0.21 | Why? |
| Vaccination | 6 | 2021 | 19050 | 0.20 | Why? |
| Scientific Experimental Error | 1 | 2018 | 9 | 0.19 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.19 | Why? |
| Nasopharynx | 1 | 2018 | 10224 | 0.18 | Why? |
| Serotyping | 1 | 2017 | 154 | 0.17 | Why? |
| Magnesium Sulfate | 1 | 2017 | 52 | 0.17 | Why? |
| Neisseria meningitidis, Serogroup B | 1 | 2017 | 66 | 0.17 | Why? |
| Double-Blind Method | 4 | 2021 | 5988 | 0.16 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.16 | Why? |
| Neisseria meningitidis, Serogroup C | 1 | 2016 | 46 | 0.16 | Why? |
| Haemophilus Vaccines | 1 | 2016 | 76 | 0.16 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2021 | 10649 | 0.16 | Why? |
| Meningitis, Meningococcal | 1 | 2017 | 114 | 0.16 | Why? |
| Cerebral Palsy | 1 | 2017 | 156 | 0.15 | Why? |
| Ebola Vaccines | 1 | 2017 | 126 | 0.15 | Why? |
| Adenoviridae | 2 | 2021 | 1151 | 0.14 | Why? |
| Vaccinia virus | 1 | 2017 | 346 | 0.14 | Why? |
| Antigens, Bacterial | 1 | 2017 | 330 | 0.14 | Why? |
| Validation Studies as Topic | 1 | 2014 | 121 | 0.13 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2018 | 782 | 0.13 | Why? |
| South Africa | 2 | 2021 | 3326 | 0.13 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.13 | Why? |
| Pharyngitis | 1 | 2017 | 687 | 0.12 | Why? |
| Bias | 1 | 2018 | 1109 | 0.12 | Why? |
| Immunoglobulin G | 8 | 2020 | 21571 | 0.12 | Why? |
| B-Lymphocytes | 2 | 2017 | 4418 | 0.12 | Why? |
| Bangladesh | 1 | 2018 | 1620 | 0.12 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.11 | Why? |
| T-Lymphocytes | 4 | 2021 | 6670 | 0.11 | Why? |
| Young Adult | 9 | 2021 | 93724 | 0.11 | Why? |
| Asymptomatic Infections | 2 | 2021 | 7218 | 0.10 | Why? |
| Female | 21 | 2021 | 380317 | 0.10 | Why? |
| Pakistan | 1 | 2018 | 2302 | 0.10 | Why? |
| Pain | 1 | 2018 | 1084 | 0.10 | Why? |
| Humans | 31 | 2021 | 930598 | 0.10 | Why? |
| United Kingdom | 5 | 2021 | 18046 | 0.10 | Why? |
| Child, Preschool | 6 | 2018 | 36283 | 0.10 | Why? |
| Male | 20 | 2021 | 367725 | 0.09 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.09 | Why? |
| Antibodies, Neutralizing | 5 | 2021 | 25288 | 0.09 | Why? |
| Opsonin Proteins | 2 | 2017 | 18 | 0.09 | Why? |
| Blood Bactericidal Activity | 2 | 2017 | 19 | 0.09 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.08 | Why? |
| Mothers | 1 | 2017 | 1624 | 0.08 | Why? |
| Adult | 13 | 2021 | 244371 | 0.08 | Why? |
| Enzyme-Linked Immunospot Assay | 2 | 2017 | 325 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Dexamethasone | 1 | 2017 | 2055 | 0.07 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2017 | 1475 | 0.07 | Why? |
| Premature Birth | 1 | 2017 | 2151 | 0.07 | Why? |
| HIV Infections | 2 | 2021 | 11620 | 0.07 | Why? |
| Dose-Response Relationship, Drug | 3 | 2020 | 3776 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.07 | Why? |
| Genetic Vectors | 2 | 2020 | 1600 | 0.06 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.06 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.06 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.06 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.05 | Why? |
| Adenoviruses, Simian | 1 | 2020 | 52 | 0.05 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.05 | Why? |
| Child | 3 | 2018 | 70012 | 0.05 | Why? |
| Vaccine Potency | 1 | 2021 | 339 | 0.05 | Why? |
| Analgesics, Non-Narcotic | 1 | 2020 | 164 | 0.05 | Why? |
| Infant, Newborn | 2 | 2017 | 23105 | 0.05 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2020 | 593 | 0.05 | Why? |
| Protein Subunits | 1 | 2020 | 755 | 0.04 | Why? |
| Acetaminophen | 1 | 2020 | 326 | 0.04 | Why? |
| Visual Analog Scale | 1 | 2017 | 151 | 0.04 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.04 | Why? |
| Blood | 1 | 2017 | 274 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2021 | 1517 | 0.04 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.04 | Why? |
| Immunity, Cellular | 2 | 2020 | 3614 | 0.04 | Why? |
| Aged | 3 | 2021 | 215776 | 0.04 | Why? |
| Infant Mortality | 1 | 2017 | 268 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Phagocytosis | 1 | 2017 | 409 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Neuroprotective Agents | 1 | 2017 | 240 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.03 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.03 | Why? |
| Placebos | 1 | 2017 | 629 | 0.03 | Why? |
| Fetal Blood | 1 | 2017 | 573 | 0.03 | Why? |
| Safety | 1 | 2021 | 1583 | 0.03 | Why? |
| Infant, Premature | 1 | 2017 | 883 | 0.03 | Why? |
| Glycoproteins | 1 | 2017 | 615 | 0.03 | Why? |
| Gestational Age | 1 | 2017 | 1488 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Immunity, Herd | 1 | 2019 | 1011 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Interferon-gamma | 1 | 2020 | 2711 | 0.03 | Why? |
| Lymphocyte Subsets | 1 | 2017 | 987 | 0.03 | Why? |
| Asia | 1 | 2017 | 2399 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Data Interpretation, Statistical | 1 | 2014 | 657 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2017 | 17020 | 0.02 | Why? |
| Drug Prescriptions | 1 | 2017 | 1062 | 0.02 | Why? |
| Africa | 1 | 2017 | 2986 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Prenatal Care | 1 | 2017 | 1314 | 0.02 | Why? |
| Temperature | 1 | 2017 | 2305 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.02 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2020 | 37182 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.02 | Why? |
| Periodicals as Topic | 1 | 2018 | 1492 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Immunization Programs | 1 | 2017 | 2006 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Feces | 1 | 2017 | 4235 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Time-to-Treatment | 1 | 2017 | 5883 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.01 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2014 | 11304 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Prognosis | 1 | 2014 | 32490 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.00 | Why? |
Voysey's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(156)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(250)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_